Carvalho A C, Vaillancourt R A, Cabral R B, Lees R S, Colman R W
JAMA. 1977 Feb 28;237(9):875-8.
Thirteen asymptomatic women taking oral contraceptives (OCs) were compared with normal subjects. Platelet aggregation and serotonin (tagged with carbon 14) release with adenosine diphosphate, epinephrine, and collagen did not differ from controls. Activation of the intrinsic coagulation pathway was evaluated by measurements of factor XII, prekallikrein, and kallikrein inhibitors. Women taking OCs had normal factor XII levels, moderately elevated prekallikrein levels, and decreased kallikrein inhibitor levels, a pattern not consistent with activation of the intrinsic pathway. The concentration of heavy molecular weight fibrinogen derivatives (HMWFD) was significantly elevated (P less than .001). In contrast, fibrin and fibrinogen degradation products in serum were lower than normal (P less than .05). The increased HMWFD concentration may reflect activation of the coagulation system not mediated by factor XII activation nor potentiated by decreased antithrombin III. Thus, plasma coagulation abnormalities rather than platelet changes may be the factor that predisposes women taking OCs to thromboembolic disorders.
将13名服用口服避孕药(OCs)的无症状女性与正常受试者进行了比较。服用OCs的女性血小板聚集以及二磷酸腺苷、肾上腺素和胶原诱导的血清素(用碳14标记)释放与对照组无差异。通过测量因子XII、前激肽释放酶和激肽释放酶抑制剂来评估内源性凝血途径的激活。服用OCs的女性因子XII水平正常,前激肽释放酶水平中度升高,激肽释放酶抑制剂水平降低,这种模式与内源性途径的激活不一致。高分子量纤维蛋白原衍生物(HMWFD)的浓度显著升高(P小于0.001)。相比之下,血清中的纤维蛋白和纤维蛋白原降解产物低于正常水平(P小于0.05)。HMWFD浓度的增加可能反映了凝血系统的激活,这种激活不是由因子XII激活介导的,也不会因抗凝血酶III减少而增强。因此,血浆凝血异常而非血小板变化可能是服用OCs的女性易患血栓栓塞性疾病的因素。